AntriaBio, Inc. – “An Update on Basal Insulins from ADA”

Publishing & Media

Share Tweet

AntriaBio, Inc. – “An Update on Basal Insulins from ADA”

New York, NY / June 25, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman’s Blog, written by the Company’s Chairman and CEO, Mr. Nevan Elam. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Following the Company’s attendance at the American Diabetes Association’s (ADA) 74th Scientific Sessions, Mr. Elam shares highlights from the event. In his blog post, he touches on updates on the developments for other basal insulin therapies. In regard to the other companies trying to improve current basal insulin therapies, Mr. Elam remarks, “It validates the work we are doing on AB101, our unique formulation of a once-weekly basal insulin.” Read the full blog post from Mr. Nevan Elam on (

About AntriaBio, Inc.

AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. AntriaBio's development strategy combines FDA approved pharmaceutical agents with its proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes. For more information visit:

About is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. 

SOURCE: The Chairmans Blog